GUTS fractyl.com Earnings growth forecast for next year
Fractyl Health, Inc. (GUTS) is implementing proprietary hydroablation to combat diabetes, creating an alternative to injections. The expected EPS growth rate for the coming year confirms this potential, with the figure standing at -24.60. However, popular weight-loss drugs and the complexities of clinical trials are exerting pressure. High testing costs and strict FDA oversight protect the niche from new entrants.
GUTS (Fractyl Health Inc.): analytical breakdowns and indicator data
- share price and consensus valuation forecast:
- market capitalization data:
- book capitalization indicators:
- debt and solvency information:
Total Debt to Capital Fractyl Health, Inc.|GUTS - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Fractyl Health, Inc|GUTS - Company Total Debt Obligations|Debt to Book Capitalization Ratio Fractyl|GUTS - Company Long-Term Liabilities|Company Short-Term Debts Fractyl Health|Quick Liquidity fractyl.com
- net income and valuation ratios data:
GUTS - Final Profit|Projected Future Earnings Fractyl Health, Inc.|GUTS - P/E Multiple|Forward P/E Multiple Fractyl Health Inc.|GUTS - Price/Earnings to Growth Multiple|Enterprise Value to EBITDA Ratio Fractyl Health|GUTS - Company profit before taxes, interest and amortization|Net earnings per share for the last 12 months Fractyl Health|GUTS - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months fractyl.com|GUTS - Earnings per share growth in current year|Expected earnings per share growth for next year Fractyl Health, Inc.
- total revenue and sales volume data:
Initial company analysis:GUTS, fractyl.com
Fractyl Health, Inc. (GUTS) is achieving a breakthrough in endocrinology by developing metabolic engineering methods to cure type 2 diabetes without injections. This forward-looking earnings per share (EPS) growth forecast consolidates expert expectations for EPS dynamics, reflecting market confidence in the commercialization of these innovations. The positive trend in the forward EPS growth forecast confirms the fundamental price stability and the business's scaling potential.
Analysis of competing companies
ASND (Ascendis) - Earnings growth forecast for next year|Earnings growth forecast for next year Madrigal Pharmaceuticals|Earnings growth forecast for next year CORT|Net earnings per share growth forecast for next year RYTM (Rhythm Pharma)|Net earnings per share growth forecast for next year akerotx.com AKRO|Metsera Therapeutics (MTSR) - Expected net earnings per share growth next year|MLTX - Net earnings per share growth forecast for next year|CRNX: Net earnings per share growth forecast for next year|NAMS: Earnings growth forecast for next year|SLNO - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Amicus Corp|89bio Pharma (ETNB) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year agios.com (AGIO)|Expected earnings per share growth for next year structuretx.com GPCR|Net earnings per share growth forecast for next year MiMedx Group Inc MDXG|Expected earnings per share trend next year RZLT|lexpharma.com - Earnings growth forecast for next year|MBX (MBX Biosciences Inc) - Projected earnings per share growth rate for next year|ALT: Earnings growth forecast for next year|Aardvark Therapeutics Inc - Expected earnings per share trend next year|SGMT (Sagimet Biosciences, Inc.) - Earnings growth forecast for next year|Earnings growth forecast for next year BioAge|Earnings growth forecast for next year BMEA|Expected earnings per share growth for next year Quince Therapeutics, Inc. QNCX|Earnings growth forecast for next year VTVT (vTv Therapeutics Inc.)|Expected earnings per share trend next year ATPC|Pluristem Therapeutics - Earnings growth forecast for next year|Consensus forecast of earnings per share growth for next year synlogictx.com SYBX|LPCN: Earnings growth forecast for next year|Matinas BioPharma Holdings, Inc. - Expected earnings per share trend next year|SPRB (Spruce Biosciences Inc.) - Earnings growth forecast for next year|galecto.com (GLTO) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Carmell Therapeutics (CTCX)|LUMO (Lumos Pharma Inc) - Expected earnings per share trend next year|Net earnings per share growth forecast for next year organovo.com ONVO|Radius Health (RDUS) - Expected net earnings per share growth next year
